[size= 14px]The S. epidermidis LTA monoclonal antibody is designed to recognize lipoteichoic acid on Staphylococcus epidermidis, aiding in targeted immune defense. Its non-fucosylated form enhances antibody-dependent cellular cytotoxicity, making it a promising tool for therapeutic interventions, especially against infections caused by this opportunistic pathogen in immunocompromised individuals and neonates.[/size]